Brian Dorsey - Nov 13, 2025 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
Chief Operating Officer
Signature
/s/ Kathleen Scott, Attorney-in-Fact
Stock symbol
SPRY
Transactions as of
Nov 13, 2025
Transactions value $
-$176,080
Form type
4
Date filed
11/14/2025, 06:43 PM
Previous filing
Jan 3, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Dorsey Brian Chief Operating Officer C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO /s/ Kathleen Scott, Attorney-in-Fact 2025-11-14 0001380762

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Options Exercise $14K +21.8K +202.32% $0.64 32.6K Nov 13, 2025 Direct F1
transaction SPRY Common Stock Sale -$190K -21.8K -66.92% $8.71 10.8K Nov 13, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -21.8K -100% $0.00 0 Nov 13, 2025 Common Stock 21.8K $0.64 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,628 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") on December 31, 2024 and 3,137 shares acquired under the ESPP on June 30, 2025.
F2 The weighted average sale price for the transaction report was $8.7067, and the range of prices was between $8.63 and $8.835. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3 Immediately exercisable.